| Bladder Cancer | |
|
Trial Status OPEN TO ENROLLMENT Protocol Number: SPI-612 03/2009 - Present Sponsor: Spectrum Pharmaceuticals Title: A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Phase 3 Trial of Single-Dose Intravesical EOquin as a Surgical Adjuvant Instilled in the Early Postoperative Period in Patients Undergoing Transurethral Resection for Noninvasive Bladder Cancer. Purpose of Study The purpose of this study is to evaluate the recurrence rate of bladder cancer at two years in patients with low grade bladder tumors, who have undergone Transurethral Resection of bladder tumor (TUR-BT) plus EOquin® versus those who receive TUR-BT plus placebo. This study will enroll adult patients with noninvasive bladder cancer. For further information, click here. List of Completed Trials for Bladder Cancer Protocol Number: TRI-00-0001 02/2000 – 01/2007 Sponsor: Schering Plough Title: A multicenter trial of induction and six courses of three week maintenance with BCG versus BCG plus Interferon Alfa-2B in the treatment of superficial bladder cancer. Clinical Research Coordinators: Patricia Edwards, RN (336) 274-1114 ext. 5322 Karen Michael, RN (336) 274-1114 ext. 5328 E-mail address: research@allianceurology.com |
|
All trademarks and registered trademarks are of their respective companies.
Site powered by Medfusion, Inc.
Website Graphics by Vintage Marketing